Key result
In vitro spiking experiments identified prothrombin as the major thrombogenic agent in prothrombin complex concentrates, an effect that was perfectly reversed by antithrombin and heparin.
Why the study?
What is the major thrombogenic agent in prothrombin complex concentrates?
Population
In vitro test system employing plasma from coumarin-treated patients
Comparison
Prothrombin complex concentrates spiked with… vs Typical PCC without reported thromboembolic…
Design
Preclinical
Authors
Loading...
In vitro PCC thrombogenicity assay may flag risk; leaves open clinical predictive utility pending validation.
What is the major thrombogenic agent in prothrombin complex concentrates?
This in vitro study identifies prothrombin, rather than activated factor IX, as the likely major thrombogenic agent in prothrombin complex concentrates, supporting the use of antithrombin to prevent thromboembolic complications.
Dusel et al. (2004) studied Coumarin-treated patients (plasma source). Prothrombin vs. PCC without reported thromboembolic complications was evaluated on In vitro thrombogenicity (thrombin generation assay). In vitro spiking experiments identified prothrombin as the major thrombogenic agent in prothrombin complex concentrates, an effect that was perfectly reversed by antithrombin and heparin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: